OFFICE OF CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW

Submission Dates: 2/29/00 6/28/00

NDA:	20-626/S004
Name of Drug:	Imitrex (Sumatriptan) Nasal Spray
	5 mg/100 μL, and 20 mg/100 μL
Indication of Drug:	Migraine
Type of Submission:	Pediatric Supplement
Sponsor:	Glaxo Wellcome, Research Triangle, NC
Reviewer:	Hong Zhao, Ph.D.

Introduction

Imitrex (sumatriptan) Nasal Spray was approved by the Agency on August 26, 1997 for the acute treatment of migraine in adults (NDA 20-626). This supplemental application provides information to include the acute treatment of migraine in adolescent patients, ages 12 to 17 years. Three clinical studies of sumatriptan nasal spray in adolescent patients have been conducted:

Protocol SUMB1006 -	An open-label pharmacokinetic study of sumatriptan nasal spray
	20 mg in adolescent patients (ages 12-17 years).
Protocol SUMA3005	- A double-blind, placebo-controlled study of the efficacy and
	tolerability of sumatriptan nasal spray 5 mg, 10 mg and 20 mg in
	adolescent patients (ages 12-17 years).
Protocol SUMA3006	- An open-label evaluation of the long-term (up to 12 months)
	safety and tolerability of sumatriptan nasal spray in adolescent
	patients (ages 12-17 years). This study is incorporated into the
	Four-Month Safety Update for this application.

One clinical trial of sumatriptan nasal spray in pediatric patients (Phase IV) is ongoing:

Protocol SUMA4025 - A single dose study to investigate pharmacokinetics of Sumatriptan Nasal Spray in pediatric subjects (6-11 years) outside of a migraine attack. Pediatric patients are given 5 mg, 10 mg or 20 mg sumatriptan nasal spray depending on their age and weight.

Pharmacokinetics Study Review

Study Design

Protocol SUMB1006 is a single dose, single center study in 21 male and female adolescent migraineurs to determine the pharmacokinetics and tolerability of 20 mg sumatriptan nasal spray administered outside of an attack. Blood samples were collected pre-dosing and at 15, 30, 45 minutes, 1, 2, 3, 4, 6 and 8 hours post-dosing for sumatriptan concentration determination.

Sumatriptan Concentration Determination

A validated HPLC method with electrochemical detection was used to determine serum sumatriptan concentrations. The limit of quantitation (LOQ) was 0.25 ng/ml. The assay covered the range of 0.25-20 ng/ml sumatriptan with coefficient of variation < 10%.

Pharmacokinetic Results

Of the twenty-one adolescent migraineurs (12 boys and 9 girls aged 12.3 to 17.5 years and weighing 45.0-59.5 kg) enrolled and treated in the study, 19 subjects completed the study and two subjects withdrew from the study due to not willing to continue blood sampling procedures. An apparatus failure led to a loss of a number of results, resulting in a population of 16 subjects with complete bioanalytical data. The pharmacokinetic results are shown below:

Single Dose (20 mg	Batch 7B12) Intranasal Sn	ray in Adolescent	Migraineurs
Dingle Dose (20 mg	Dutch / D12) minanasai Sp	nuy in muoieseem	manduneurs

	C _{max} (ng/ml)	AUC _∞ (ng.h/ml)	T _{max}	t _{1/2} (h)
Adolescents	15 (43)	59 (30)	2.0 (0.5-3.0)	2.1 (24)

SUMB1006, N=16. Data reported as arithmetic means and (CV%). T_{max} reported as the median and range.

These Pharmacokinetic parameters show a large degree of variability (CV% 43% on C_{max}) due to a variety of factors such as deposition of intranasal solution in the nasal passages, the extent of the dose that is swallowed and perhaps variable presystemic metabolism. This inter-subject variability was also observed in adults:

Single Dose ($(20 \text{ mg})^{-1}$	Intranasal Si	prav in	Healthy	Male	Adults	(C93-065, N=24)
~			pres in			1000000	(0)0 000,1(=.)

	C _{max} (ng/ml)	AUC _∞ (ng.h/ml)	T _{max}	t _{1/2} (h)
Adults	14 (44)	50 (32)	1.5 (0.3-3.0)	1.9 (23)

Data reported as arithmetic means and (CV%). T_{max} reported as the median and range.

• These pharmacokinetic data show that after single dose of Imitrex nasal spray, systemic exposure to sumatriptan in adolescents and adults are comparable.

Population Pharmacokinetic Analysis

The exploration of the relationships between demographic covariates (i.e., age, weight, height and gender) and non-compartmental PK parameters (i.e., C_{max} , AUC, CL/F) did not reveal any significant effect. Population pharmacokinetic analysis (n=21) showed that clearance and volume of distribution increases with body size in the adolescent population [CL/F = 330(L/h) x BW(kg)/59.5; Vd/F=70.8 (L/yr) x Age].

Safety and Tolerability

Safety and tolerability were assessed using laboratory safety parameters, vital signs, ECG and adverse event monitoring. According to the sponsor, sumatriptan was well tolerated. All adverse events were mild to moderate in intensity and resolved spontaneously.

Sponsor's Proposed Changes to Labeling

The Clinical Pharmacology Section of the labeling has been changed to describe results from *Study SUMB 1006* as follows:

Comment 1

The results of the pharmacokinetics studies demonstrate that systemic exposure to sumatriptan in adolescents and adults are similar after administration of single dose of Imitrex nasal spray.

(b) (4)

OCPB Suggested Labeling:

Pharmacokinetics: Replace the first sentence with the following one:

In a study of 20 adult female volunteers treated with 5 and 20 mg of intranasal sumatriptan, mean C_{max} was 5 and 14 ng/ml, and AUC_{∞} was 19 and 53 ng.hour/ml, respectively, and $t_{1/2}$ was 2.0 hours.

And add the following sentences to the end of the paragraph:

In 16 adolescent patients aged 12 to 17 years with migraine treated outside of an attack with 20 mg of intranasal sumatriptan, the pharmacokinetic parameters were not significantly different from adults. Mean C_{max} was 15 ng/ml; AUC_{∞} was 59 ng.hour/ml; and $t_{1/2}$ was 2.1 hours.

Add the following paragraph to Age factor under Special Populations subsection: *Special Populations*

Age: The pharmacokinetics of 20 mg of intranasal sumatriptan in 16 adolescent male and female patients (aged 12 to 17 years) suffering from migraine outside of a migraine attack were similar to that in healthy male adult subjects.

Please convey Comments 1 & OCPB suggested labeling to Medical Review Officer.

Hong Zhao, Ph.D._____

RD/FT Initialed by Raman Baweja, Ph.D._____

cc: NDA 20-626/S-004 Imitrex (Sumatriptan) Nasal Spray, HFD-120, HFD-860 (Zhao, Baweja, Mehta), Central Documents Room (CDR-Biopharm)

APPEARS THIS WAY ON ORIGINAL

Attachment

Synopsis

Document Number: GM1998/00376/01 Protocol Number: SUMB1006.

NAME OF COMPANY: Glaxo Wellcome NAME OF FINISHED PRODUCT: [xx] NAME OF ACTIVE INGREDIENT(S): [xx]	INDIVIDUAL STUDY TABLE REFERRING TO PART IV OF DOSSIER Volume: [xx] Page: [xx]	(FOR NATION/ USE ONLY)	AL AUTHORITY				
Title: An open, uncontrolled study in adolescent subjects with migra	to investigate the single dose pharmaco ine outside of a migraine attack	kinetics of sumati	riptan nasal spray				
Investigator(s): Dr Michael Christ	lensen						
Study center(s): University of Ten	nnessee, College of Pharmacy, Memphis	, TN, USA					
Publication(s): NA							
Study period: 7 July 1998, - 5 October 1998 Clinical phase: I							
Objectives: To evaluate the pharmacokinetics and assess the safety of sumatriptan nasal spray (20mg) administered to adolescent migraineurs outside of a migraine attack							
Methodology: Single dose open study, no comparator, single centre							
Number of subjects: 21 subjects	were enrolled in the study, two withdrew	their consent					
	n: male or female adolescents with migra nerwise; suffering from at least 2 but no m r month over the last 2 months						
Test product, dose and mode of a	administration, batch no.: sumatriptan na	sal spray 20mg	Batch 7B12				
Duration of treatment: single dos	e study						
Reference therapy, dose and mode of administration, batch no.: none							
Criteria for evaluation: pharmacokinetics (non-compartmental analysis, PK modelling); safety (vital signs, ECG, laboratory safety, adverse events)							
Statistical methods: descriptive statistics only							
spray; two subjects withdrew from adverse events were mild to mod- pharmacokinetic parameters (n=1 Cmex was 13.89(10.96, 17.60) ng/	hty-one subjects were treated with single in the study; 19 completed the study. Sum- erate in intensity and resolved spontaneo 6) of sumatriptan nasal spray were not si mL; AUC, was 57.32 (47.61, 69.02)ng/m nat clearance and volume of distribution i	natriptan was wel usly. Non-compa gnificantly differe L.hr and t 1/2 was	I tolerated. All antmental int from adults; 2.02(1.77, 2:32)				

DRUG FORMULATION

Imitrex[®] Nasal Sprays are single dose units containing GR43175 nasal solution delivering 5 or 20mg GR43175.

The GR43175 is presented as a solution

(b) (4)

(b) (4)

The formula for Imitrex[®] Nasal Sprays are summarized in the following table:

Name of Constituents Quantities (mg/mL of solution) GR43175X (b) (Monobasic Potassium Phosphate NF (b) (Dibasic Sodium Phosphate USP, anhydrous (b) (Sulfuric Acid NF* (b) (Sodium Hydroxide NF** (b) (Purified Water USP (b) (Nominal Strength	5mg	(b) (4) 20mg
Monobasic Potassium Phosphate NF Dibasic Sodium Phosphate USP, anhydrous Sulfuric Acid NF* Sodium Hydroxide NF**	Name of Constituents	Quantities (r	ng/mL of solution)
Dibasic Sodium Phosphate USP, anhydrous Sulfuric Acid NF* Sodium Hydroxide NF**	GR43175X		(b) (
Sulfuric Acid NF* Sodium Hydroxide NF**	Monobasic Potassium Phosphate NF		
Sodium Hydroxide NF**	Dibasic Sodium Phosphate USP, anhydrous		
	Sulfuric Acid NF*		
Purified Water USP	Sodium Hydroxide NF**		
	Purified Water USP		

Study (Report)	Route of	Dose	Regimen	Population	Cmax	Tnax	AUC.	Half-life
	Administration /			Male/Female	ng/mL	hours	ng.h/mL	hours
	Dosage Form							
GM1998/00376/01	Intranasal	20mg	Single dose	Adolescent	15 (43)	2 (0.50-3.00)	59 (30)	2.1 (24)
Protocol SUMB1006	Nasal spray			12/9				
GCP/93/065	Intranasal/ Nasal spray	20mg	Single dose	Adult healthy subjects *	14 (44)	1.5 (0.25-3.0)	50 (32)	1.9
Protocol C93-065				24/0				(23)

Pharmacokinetic parameters are reported here an arithmetic means and (CV%); the geometric mean and 95% coafidence intervals are reported in the text and individual study reports. T_{max} is reported as the median and range.

*Study C93-065

Figure 1. Median sumatriptan concentrations in adolescent after treatment with 20mg sumatriptan nasal spray: all subjects




Table 7. Population estimates for derived Sumatriptan Pharmacokinetic Parameters (NONMEM analysis: final model)

Parameter		Estimate (Se)	unit
Apparent Clearance	C1/F = THETA(1)*WTKG/59.5	330 (6%)	L/h
Apparent Volume of distribution	Vd/F = THETA(2)*AGE	70.8 (10%)	L/yr
Rate constant of absorption (first order abs)	Ka = THETA(3)	8.25 (90%)	h-1
Duration of zero order absorpyion	D2 = THETA(4)	1.22 (15%)	h
Lag-time of zero order asborption	ALAG2= THETA(5)	0.416 (35%)	h
Fraction of the dose absorbed by first order	F1 = THETA(6)	0.423 (30%)	-
Between subject variability on Clearance	ETA(1)	248	-
Between subject variability cn volume	ETA (2)	43%	-
Between subject variability on lag time	ETA (3)	618	-
Between subject variability on fraction of dose absorbed by first order	ETA (4)	538	-
Residual error	EPS	17%	_

/s/

Hong Zhao 11/28/00 01:59:19 PM BIOPHARMACEUTICS

Please sign off

Raman Baweja 11/28/00 02:28:20 PM BIOPHARMACEUTICS